Mentari Therapeutics, formerly InMed Pharmaceuticals, completed its merger and will begin trading on Nasdaq under the ticker MTRI on November 9, 2026. The company redomesticated to Nevada and raised about $490 million through private financings. Mentari focuses on developing advanced migraine therapies, including MT-001 and MT-002, aiming to offer better treatment options. This move positions Mentari for growth in the biotech sector with a strong pipeline targeting migraine prevention.
InMed Pharmaceuticals' merger completion with Mentari Therapeutics provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 07, 2026 04:02 WIB: out of 150 priced US health-sector stocks, 77 rose and 72 fell. Notable movers include HALO at USD 103.91 with a 1-day change of -15.49% and 100% sell order activity, BKD at USD 9.14 down 15.45% but with 100% buy order activity, and SMMT at USD 16.30 up 14.87% with 59% buy orders and a typical hold time of 19 days.
Arcutis Biotherapeutics awarded 58,500 restricted stock units and options for 17,000 shares to six new employees as an inducement to join the company. The grants, approved under Nasdaq Listing Rule 5635(c)(4), vest over four years with specific sched...
The music duo for KING + COUNTRY released the Drummer Boy (Original Motion Picture Soundtrack) to coincide with the nationwide launch of their Christmas film DRUMMER BOY. The soundtrack features original songs by Joel and Luke Smallbone, reimagined C...
HMG Strategy is holding its first Tennessee C-Level Technology Leadership Summit on November 13 at W Nashville, bringing together CIOs, CISOs, CTOs, and senior tech executives from across Tennessee and the Mid-South. The summit will focus on AI, cybe...
Two large transfers of Tether USDt (USDT) totaling over 81 million tokens were recorded moving from unidentified wallets to Coinbase in early November. On November 1, 40 million USDT moved to Coinbase, followed by a 41,048,700 USDT transfer on Novemb...
OpenAI has raised $11 billion so far in a new funding round valuing the company at $1.25 trillion, with the round expected to close at around $20 billion. This funding round is smaller than the initially targeted $30 billion. The AI market faces unce...
